Rockwell Medical announced today that it presented new in vitro data at the American Society of Nephrology's Renal Week on its lead drug candidate Soluble Ferric Pyrophosphate (SFP). 

 



The study evaluated the kinetics of iron transfer from SFP to apo-transferrin (apo-Tf). Results showed that all available iron present in SFP was delivered to both iron-binding sites on human apo-transferrin, rapidly and completely. Further, 50% of iron uptake was complete within one minute, while there was approximately 90% saturation of the iron- binding sites on transferrin, the blood plasma protein for iron ion delivery, within 10 minutes. 
  



Ajay Gupta, Chief Scientific Officer of Rockwell, said, "This in vitro study provides important information about SFP by demonstrating iron kinetics similar to that of ferric-NTA, which is known to transfer iron rapidly and completely to apo-transferrin. These data suggest that SFP has potential to overcome inflammation-induced RES block and iron-induced redox reactions."